Novartis AG (NVS)
| Market Cap | 261.94B +4.3% |
| Revenue (ttm) | 56.69B +2.7% |
| Net Income | 12.76B -6.6% |
| EPS | 6.61 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 20.53 |
| Forward PE | 14.83 |
| Dividend | $3.08 (2.24%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 2,876,486 |
| Open | 138.14 |
| Previous Close | 137.70 |
| Day's Range | 137.30 - 139.45 |
| 52-Week Range | 121.57 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 157.83 (+14.8%) |
| Earnings Date | Oct 27, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $157.83, which is an increase of 14.80% from the latest price.
News
Novartis upgraded to Hold from Reduce at HSBC
HSBC upgraded Novartis (NVS) to Hold from Reduce with a CHF 110 price target
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Company reported that its Phase 3 HARBOR study of del-desiran and Phase 3 HORIZON study of pelacarsen d...
Anthropic has the right mindset when it comes to AI safety, says board Member Vas Narasimhan
Vas Narasimhan, CEO at Novartis and board member of Anthropic, joins 'Squawk on the Street' to respond to the recent statements of former researcher who warns that AI may soon prove to be a threat to ...
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss disappointing drug trial results soon after acquiring Avidity, the response to investors and more.
Novartis CEO on drug trial setbacks: We have the pipeline and replacement power to grow
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss disappointing drug trial results soon after acquiring Avidity, the response to investors, and more.
Novartis price target lowered to CHF 135 from CHF 142 at Citi
Citi lowered the firm’s price target on Novartis (NVS) to CHF 135 from CHF 142 and keeps a Buy rating on the shares.
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Dyne Therapeutics (DYN) to $36 from $45 and keeps an Overweight rating on the shares. The analyst says Novartis’ (NVS) Phase 3…
Company News for Sep 9, 2026
Companies In The Article Are:QCOM,ROIV,BE and NVS
Novartis downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis last night downgraded Novartis (NVS) to Hold from Buy with a price target of CHF 120, down from CHF 140. The firm cites pelacarsen and…
Market Today: Novartis Plunges on Drug Trial Failures; US Market Drops
Market Today: Novartis Plunges on Drug Trial Failures; US Market Drops
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
European Markets Steady Amid Novartis Setbacks (NVS)
European Markets Steady Amid Novartis Setbacks (NVS)
Novartis AG (NVS) Shares Fall 13.9% -- GF Value Says Still Overvalued
Novartis AG (NVS) Shares Fall 13.9% -- GF Value Says Still Overvalued
Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tessa Romero downgraded Dyne Therapeutics (DYN) to Underweight from Neutral with a price target of $10, down from $17. The firm believes Novartis’ (NVS) Phase 3 trial miss…
Novartis downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis downgraded Novartis (NVS) to Hold from Buy with a CHF 120 price target
Novartis initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Novartis (NVS) with a Sector Perform rating and CHF 120 price target The unexpected pelacarsen failure and del-desiran DM1 setback have “dampened momentum” and highli...
Eli Lilly Stock (LLY) Falls on News of Competitor Novartis’ Cholesterol Drug Setback
Eli Lilly’s ($LLY) stock is down 2% on reports that rival Novartis’ ($NVS) new cholesterol drug failed a closely watched cardiovascular trial.
Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’
After Sarepta (SRPT) competitor Novartis (NVS) reported that its Phase 3 HARBOR trial of del-desiran in myotonic dystrophy type 1 failed to achieve statistical significance on the primary endpoint of…
Swiss Stocks Slide On Novartis Experimental Drug Setback
(RTTNews) - Save for a few minutes at the start, the Switzerland market languished in negative territory on Tuesday, due largely to heavy selling at the drugmaker Novartis counter.
Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone
Mizuho analyst Uy Ear believes Sarepta’s (SRPT) selloff due to Novartis’ (NVS) failed HARBOR Phase 3 study of del-desiran in DM1 is overdone. In the firm’s view, the press release…
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapie...
H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss
H.C. Wainwright reiterates a Sell rating on Sarepta (SRPT) with a $5 price target after Novartis (NVS) said its Phase 3 study of del-desiran missed its placebo-controlled primary endpoint. The…
Novartis (NVS) Faces Setbacks in Clinical Trials, Impacting Pipeline and Stock Value
Novartis (NVS) Faces Setbacks in Clinical Trials, Impacting Pipeline and Stock Value
Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails
Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails